Pricing Log in Create free account
Friday 6 November 2026 Export GH’s income statement to Excel — free account

Guardant Health, Inc.

GH Healthcare Diagnostics & Research

Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024.

Revenue
+36.1%
EPS
−25.7%
Free cash flow
+18.7%
Total debt
+34.8%

Quarter to September 2026, against a year earlier

154.16 14.42 −8.55%
Market cap
$20.6B
P/E
0.0×
Fwd P/E
−55.6×
Dividend yield
—
F-score
5/9
Altman Z
2.02
Beneish M
−2.78
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Insider Decisions last twelve months

Bought, $m 0.08
Sold, $m 167.07
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — 1 — — — — —
Sell 10 2 — 4 2 9 11 1 6 5 2 —
Insider Ownership 4.21%

Capital & Financial Ratios $m

Size
Market Cap 20,590.00
Revenue ttm 1,278.88
Net income ttm (485.07)
Free cash flow ttm (232.15)
Net debt Q 1,502.41
Valuation
P/E 0.00
Forward P/E (55.60) (negative: loss-making)
Price / sales 16.20 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 3.60 (at or above 1.5: strong)
Debt / equity Q (5.45) (negative: negative equity)
Interest coverage Q (98.71)
Growth
Revenue growth Q +36.12% (above 0%: growing)
Operating income growth Q −34.12% (below 0%: shrinking)
EPS, this year +2.18%
EPS, next year A +34.66% (at or above 15%: strong)
Revenue, next year A +38.39% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +57.16% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 16.6×, against a ten-year median of 13.4×; over the ten years it ranged from 2.2× in 2018 to 62.9× in 2019.
P/S against its own 10 years 56.47%
10-year low 10-year high
EV/Sales against its own 10 years 56.71%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,169 840 1,202 —
Receivables 89 110 138 187
Inventory 62 71 86 93
Other — — — —
1,347 1,055 1,466 1,343
2023 2024 2025 Q'26
Payables 52 39 54 103
ST’ Debt — — — —
Other — — — —
206 226 303 373

Compound Annual Growth %

10y 5y 3y
Sales — 27.92% 29.75%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.40 Actual −0.42

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.48 −0.39 Beat by 0.09
Q4 FY25 −0.42 −0.50 Miss by 0.08
Q1 FY26 −0.47 −0.45 Beat by 0.02
Q2 FY26 −0.40 −0.42 Miss by 0.02
Q3 FY26 −0.29 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.85) (0.90) (0.93) — —
’25 (0.77) (0.80) (0.74) (1.00) (3.32)
’24 (0.94) (0.84) (0.88) (0.90) (3.56)
’23 (1.30) (0.67) (0.73) (1.58) (4.28)
’22 (1.21) (2.25) (1.58) (1.36) (6.41)
’21 (1.09) (0.96) (1.06) (0.89) (4.00)
’20 (0.29) (0.57) (0.78) (0.94) (2.60)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 302 335 361 — —
’25 203 232 265 281 982
’24 168 177 191 202 739
’23 129 137 143 155 564
’22 96 109 117 127 450
’21 79 92 95 108 374
’20 68 66 75 78 287
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (66) (58) (24) — —
’25 (63) (60) (35) (26) (185)
’24 (30) (94) (51) (65) (240)
’23 (74) (94) (78) (79) (325)
’22 (29) (112) (78) (91) (309)
’21 (16) (63) (53) (77) (209)
’20 (13) (23) (8) (59) (104)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (71) (70) (37) — —
’25 (67) (66) (46) (54) (233)
’24 (37) (99) (55) (83) (275)
’23 (82) (101) (80) (83) (345)
’22 (51) (135) (100) (101) (387)
’21 (26) (81) (75) (102) (284)
’20 (41) (33) (18) (67) (158)
Fiscal quarters ending in the months shown.

Valuation

The price implies free cash flow after share-based pay growing 39.0% a year for ten years.

Implied
39.0%
Open the model

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 25 50 91 214 287 374 450 564 739 982 1,279 +50.2% 1,359 1,837 2,494 +36.4%
Gross margin, % 12.38 36.56 52.33 67.01 67.73 67.11 65.23 59.74 60.79 64.46 65.19 +52.1 pt
EBT (46) (83) (84) (70) (246) (384) (653) (479) (435) (418) (486) +27.7%
EBT margin, % (182.71) (166.96) (92.92) (32.52) (85.76) (102.89) (145.36) (84.90) (58.87) (42.52) (37.99) +140.2 pt
Net income (46) (83) (84) (68) (246) (385) (655) (479) (436) (416) (485) +27.7%
Per share, $
Per share, $ Revenue 1.93 3.96 2.98 2.37 2.94 3.69 4.40 5.04 6.02 7.83 9.51 +16.8%
Earnings (3.53) (6.61) (2.80) (0.84) (2.60) (4.00) (6.41) (4.28) (3.56) (3.32) (3.68) (0.7%)
Cash flow (2.81) (5.74) (2.37) (0.52) (1.07) (2.06) (3.03) (2.90) (1.95) (1.47) (1.29) (6.9%)
Capex (0.14) (0.53) (0.66) (0.23) (0.55) (0.74) (0.76) (0.18) (0.29) (0.39) (0.44) +12.3%
Free cash flow (2.95) (6.27) (3.04) (0.75) (1.62) (2.80) (3.79) (3.08) (2.24) (1.86) (1.73) (5.0%)
Book value 0.00 24.53 15.89 8.81 13.32 6.37 0.59 1.42 (1.14) (0.79) (2.05) n/m
Shares, m 13 13 30 91 98 101 102 112 123 125 131 +28.6%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 5.88 5.88 12.61 33.02 43.83 27.12 6.14 5.26 5.07 13.04 16.20 15.8
P/B 0.00 0.00 2.37 8.87 9.68 15.71 45.84 18.71 0.00 0.00 0.00 10.1
EV/Sales 1.94 1.94 7.99 30.77 40.38 27.66 6.42 5.21 5.48 13.35 16.55 14.1
EV/FCF (1.60) (1.60) (7.84) (100.17) (73.28) (34.23) (7.13) (8.09) (13.84) (52.23) (84.67) (30.0)
Cash, $m
Cash, $m Operating cash flow (37) (72) (72) (47) (104) (209) (309) (325) (240) (185) (173) +19.7%
Capex (2) (7) (20) (21) (54) (75) (77) (20) (35) (48) (59) +44.4%
Free cash flow (38) (79) (92) (68) (158) (284) (387) (345) (275) (233) (232) +22.2%
Balance, $m
Balance, $m Working capital 89 223 422 525 1,822 919 998 1,141 830 1,163 970 +33.1%
Net debt (78) (221) (412) (483) (989) 202 126 (29) 303 302 1,502 n/m
Shareholders’ equity — 309 483 798 1,298 645 60 159 (140) (99) (276) n/m
Returns, %
Returns, % ROA (26.90) (51.90) (18.29) (9.76) (15.69) (18.13) (34.32) (28.23) (26.67) (23.79) (30.68) +3.1 pt
ROIC 0.00 (54.57) (81.60) (16.31) (51.42) (30.32) (182.59) (271.47) (170.17) (134.56) (25.68) (134.6) pt
ROE 31.71 61.09 (58.31) (11.81) (24.21) (41.75) (185.65) (438.13) (4,584.50) 348.42 153.90 +316.7 pt
People
People Employees — 348 454 622 864 1,373 1,793 1,779 2,021 2,506 — +28.0%
Revenue/emp, $m 0.00 0.14 0.20 0.34 0.33 0.27 0.25 0.32 0.37 0.39 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Business profile

Updated

Guardant Health is a precision oncology company that sells blood and tissue tests used in cancer care. Its tests help clinicians choose treatments, look for cancer remaining after treatment, monitor for recurrence and screen for cancer. The company also sells testing and data services to biopharmaceutical companies developing cancer therapies.

A liquid biopsy analyzes material in a blood sample rather than requiring a new tissue biopsy. Guardant360 Liquid and Guardant360 CDx help identify tumor mutations that can inform treatment for patients with advanced cancer. Guardant360 Tissue profiles tumor tissue. Guardant Reveal uses blood to detect residual or recurring disease in early-stage colorectal, breast and lung cancers; it is also offered for monitoring treatment response in advanced solid tumors.

Guardant Health, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
MTD Mettler-Toledo International, Inc. $33.6B 37.6× 36.1× +4.48% (above 0%: growing) +18.30% (above 0%: growing) +33.01% (above 0%: growing) 63.29% 30.61% Compare
ILMN Illumina, Inc. $31.5B 35.6× 46.4× +4.15% (above 0%: growing) +48.98% (above 0%: growing) +49.80% (above 0%: growing) 73.52% 27.02% Compare
LH Labcorp Holdings Inc. $29.5B 29.5× 26.7× +6.92% (above 0%: growing) +3.18% (above 0%: growing) +44.73% (above 0%: growing) 29.08% 10.55% Compare
DGX Quest Diagnostics Incorporated $28.0B 25.0× 24.4× +9.98% (above 0%: growing) +29.36% (above 0%: growing) +6.21% (above 0%: growing) 33.65% 15.47% Compare
GH Guardant Health, Inc. $20.6B — (loss-making) — (loss-making) +36.12% (above 0%: growing) n/m +18.74% (above 0%: growing) 65.42% (36.78%)
MEDP Medpace Holdings, Inc. $17.8B 34.6× 35.8× +8.50% (above 0%: growing) +24.56% (above 0%: growing) −16.59% (below 0%: shrinking) 71.39% 23.12% Compare
RVTY Revvity Inc. $16.8B 71.9× 66.2× +4.29% (above 0%: growing) +2.17% (above 0%: growing) +26.97% (above 0%: growing) 57.43% 13.05% Compare
ICLR ICON PLC $15.1B 34.5× 34.6× −2.86% (below 0%: shrinking) n/m −8.01% (below 0%: shrinking) 24.29% 9.82% Compare
CRL Charles River Laboratories International, Inc. $14.9B 300× 89.2× −2.20% (below 0%: shrinking) +530.30% (above 0%: growing) +16.29% (above 0%: growing) 36.42% 20.62% Compare
Median of peers $22.9B 35.1× 36.0× +4.39% +24.56% +21.63% 46.93% 18.05%

All 49 Diagnostics & Research stocks →

Analyst rating changes each firm’s latest, last six months

Firm Date Action Rating Target
Barclays Oct 20, 2026 Target raised — 200.00 → 220.00
Morgan Stanley Oct 20, 2026 Target raised Outperform 185.00 → 200.00

Largest institutional holders 13F, quarter to 30 June 2026

Held by institutions 99.67%
Held by the ten largest 40.52%
Holder Shares Stake Change
Vanguard 12.27m 9.18% −284.82k
BlackRock 7.62m 5.71% −3.93m
T. Rowe Price 6.53m 4.89% −1.25m
Fidelity (FMR) 5.49m 4.11% +1.37m
Invesco 4.43m 3.32% −516.71k
Goldman Sachs 3.78m 2.83% −659.94k
Two Sigma 3.72m 2.78% −510.23k
Franklin Templeton 3.52m 2.63% +68.17k
Capital Group 3.40m 2.54% −81.71k
Deep Track Capital, LP 3.39m 2.54% +55.07k
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.

Pay and ownership Proxy statement filed 28 April 2026

Ownership

Directors and executive officers, together 5.60%
Blackrock Inc. 7.50%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Guardant Health, Inc. (GH) Latest News

6 Nov

Impact 4 · · The Motley Fool transcript
Impact 4 · · GuruFocus.com

5 Nov

Impact 4 · · Business Wire
Impact 4 · · Business Wire
Impact 3 · · MarketBeat
Impact 3 · · Investing.com
Impact 3 · · StockStory

29 Oct

Impact 4 · · Business Wire
Impact 4 · · Investing.com
Impact 3 · · Zacks

28 Oct

Impact 4 · · Simply Wall St.

26 Oct

Impact 4 · · StockStory

20 Oct

Impact 4 · · Insider Monkey
Impact 4 · · Business Wire

17 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · Simply Wall St.
Impact 4 · · Simply Wall St.

15 Oct

Impact 4 · · Business Wire
Impact 4 · · Business Wire

14 Oct

Impact 4 · · GlobeNewswire

8 Oct

Impact 4 · · Business Wire

5 Oct

Impact 4 · · Business Wire

29 Sep

Impact 3 ·

21 Sep

Impact 4 · · Investor's Business Daily

18 Sep

Impact 4 ·

16 Sep

Impact 3 ·

15 Sep

Impact 3 ·

14 Sep

Impact 4 ·

9 Sep

Impact 3 ·

8 Sep

Impact 3 ·

GH metrics, ten years each

stockrow.com/GH · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com